US-based pharmaceutical major Merck has opened a €100m R&D facility at Ballydine, Co Tipperary, Ireland.
The facility will house 70 new R&D roles, with the capacity to expand to 120 should new innovative medicines be developed. An additional investment of €6m is already planned to cater for the extra capacity.
Go deeper with GlobalData
Six drugs are currently in development at the facility, including Merck’s candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication.
Three of Merck’s five top priority candidate medicine research programmes are now based at the facility.
Ballydine will also supply materials to support Merck’s worldwide clinical research programme.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
